Key takeaways
Investment thesis
Why Lilly can keep compounding
The obesity market is moving from supply-constrained injections toward broader payer coverage, direct-pay channels, oral products and combination regimens.
- Scale: Q2 tirzepatide sales were $14.87bn, creating funding and commercial reach that smaller competitors cannot match.
- Operating leverage: 2026 revenue guidance is $85-87bn and non-GAAP performance margin guidance is 49.0-50.5%.
- Lifecycle depth: Foundayo adds oral convenience; retatrutide adds triple-agonist efficacy; EloraTZP adds amylin biology.
- Global runway: ex-US Q2 revenue grew 80%, despite a 36% realized-price decline, largely due to China reimbursement.
Why price discipline still matters
At roughly 24.0x our 2027 consensus check, Lilly needs both high EPS growth and a premium terminal multiple.
- A miss in one molecule can hit revenue growth, margin and the multiple together.
- US government, payer and cash-pay agreements exchange lower net price for volume.
- CagriSema, oral Wegovy and future Roche or Amgen products limit assumptions of permanent category dominance.
- Lilly had about $45.2bn of net debt at Q2 while funding manufacturing, acquisitions and buybacks.
Industry drivers
Access and price
The US GLP-1 Bridge program began 1 July. Government agreements contemplate $245 monthly injectable pricing for Medicare and average cash pricing near $346 through TrumpRx. Lower patient cost can expand treated lives, but net revenue per prescription falls.
Oral adoption
Novo said Wegovy pill exceeded five million prescriptions since launch and 265,000 weekly prescriptions by 17 July. Its Q2 sales were DKK 3.22bn. Lilly's newer Foundayo generated $98m in Q2.
Next-generation efficacy
CagriSema, retatrutide and amylin combinations push efficacy beyond first-generation GLP-1s. Commercial outcomes will also depend on tolerability, persistence, manufacturing and reimbursement.
Coverage at a glance
| Ticker | Price | Market cap | Fwd P/E* | YTD | Bear | Base | Bull | Prob-wtd | Stance |
|---|---|---|---|---|---|---|---|---|---|
| LLY | $1,142.85 | $1.02tn | 27.4x | +6.3% | $873 | $1,231 | $1,650 | $1,247 | |
| NVO | $37.32 | $165.7bn | 11.8x | -26.7% | $25.8 | $39.9 | $53.5 | $39.8 |
* StockAnalysis forward P/E snapshot, definitions may differ by issuer. Scenario values are estimates, not market targets. YTD uses 31 Dec 2025 closes of $1,074.68 and $50.88.
Eli Lilly NYSE: LLY
Business mix
Lilly spans cardiometabolic health, oncology, immunology and neuroscience, yet current economics are dominated by tirzepatide. Newer products outside tirzepatide grew rapidly but remained small relative to the core franchise.
* Other key products shown: Jaypirca, Ebglyss, Kisunla, Omvoh, Inluriyo and Foundayo. Source: Lilly Q2 release.
Latest quarter and guidance
| Metric | Q2 2026 | Change / context | Type |
|---|---|---|---|
| Revenue | $22.974bn | +48% YoY; volume +60%, price -13% | Fact |
| Mounjaro | $9.943bn | +91% YoY | Fact |
| Zepbound | $4.928bn | +46% YoY | Fact |
| Non-GAAP EPS | $8.38 | +33%; includes $3.03/share acquired IPR&D | Fact |
| 2026 revenue guide | $85-87bn | Raised from $82-85bn | Fact |
| 2026 non-GAAP EPS guide | $35.50-36.50 | Underlying uplift offset by IPR&D | Fact |
| 2026 normalized EPS | about $39.03 | $36 midpoint + $3.03 IPR&D | Estimate |
Bull case
- Tirzepatide volume absorbs price pressure while manufacturing investment lifts supply.
- Foundayo broadens oral access without food or water restrictions.
- Retatrutide delivers up to 20.8% weight loss in TRIUMPH-2 diabetes patients; an FDA filing is planned for Q1 2027.
- EloraTZP achieved up to 23.3% weight loss at 48 weeks compared with 14.8% for tirzepatide alone, supporting Phase 3 entry in Q4 2026.
Strongest counter-argument
Catalysts and dates
Q3 results before market open; watch product volume, realized price, performance margin and 2026 guidance.
EloraTZP Phase 3 initiation; further Foundayo and retatrutide commercialization detail.
Expected FDA decision on Novo's CagriSema, a direct competitive read-through.
Planned retatrutide US filing, subject to final regulatory pathway and completed dossier.
Falsification signals
- Two quarters where Mounjaro plus Zepbound volume growth no longer offsets net-price erosion.
- Performance-margin guidance below 49% for structural pricing or competition reasons.
- 2027 normalized EPS visibility falls below $41.
- Material retatrutide, Foundayo or EloraTZP safety, efficacy or regulatory setback.
- Free cash flow weakens while net debt continues to rise rapidly.
Valuation scenarios
| Scenario | 2027E EPS | Exit P/E | 2027 value | Present value | vs price | Weight |
|---|---|---|---|---|---|---|
| Bear | $41.0 | 23x | $943 | $873 | -23.6% | 25% |
| Base | $47.5 | 28x | $1,330 | $1,231 | +7.8% | 50% |
| Bull | $54.0 | 33x | $1,782 | $1,650 | +44.4% | 25% |
| Probability-weighted value (Estimate) | $1,247 | +9.1% | 100% | |||
Attractive entry zone: $1,000-$1,045, provided the decline is valuation-led rather than thesis-breaking. This represents about a 15-19% discount to the base value.
Sensitivity: present value at alternative 2027 EPS and P/E
| 2027E EPS → exit P/E ↓ | $41 | $44 | $47.5 | $51 | $54 |
|---|---|---|---|---|---|
| 23x | $873 | $937 | $1,012 | $1,086 | $1,150 |
| 25.5x | $968 | $1,039 | $1,122 | $1,204 | $1,275 |
| 28x | $1,063 | $1,141 | $1,231 | $1,322 | $1,400 |
| 30.5x | $1,158 | $1,243 | $1,341 | $1,440 | $1,525 |
| 33x | $1,253 | $1,344 | $1,451 | $1,558 | $1,650 |
Novo Nordisk NYSE: NVO ADR
Business mix and latest quarter
Novo remains a focused diabetes and obesity leader. Q2 net sales were DKK 78.49bn. Adjusted sales rose 7% at constant exchange rates, while adjusted operating profit rose 11%. Reported Q2 net profit fell 21% to DKK 20.99bn, affected by non-recurring items including a DKK 6.3bn non-cash pipeline impairment.
| Metric | Q2 / outlook | Context | Type |
|---|---|---|---|
| Net sales | DKK 78.488bn | +2% DKK, +3% CER | Fact |
| Adjusted sales growth | +7% CER | Excludes 340B provision effects | Fact |
| Wegovy injectable | DKK 19.484bn | +1% CER; US -22%, international +46% | Fact |
| Wegovy pill | DKK 3.218bn | DKK 3.141bn in US | Fact |
| 2026 adjusted growth | 0% to -6% CER | Sales and operating profit | Fact |
| 2027 consensus EPS | DKK 22.04 / $3.32 | Eight-analyst public snapshot; USD at 6.6421 | Estimate |
Bull case
- Wegovy pill's rapid start proves oral GLP-1 can expand the treated population.
- CagriSema produced 21.0% weight loss compared with 2.0% placebo in REDEFINE 9; an FDA decision is expected in Q4 2026.
- At about 11.2x, weak growth and pricing pressure are partly reflected.
- 2030 ambitions call for more than five multi-blockbusters and over DKK 150bn of risk-adjusted pipeline sales by 2035.
Strongest counter-argument
Catalysts and falsification
- 4 Nov 2026: Q3 results before market open; watch oral Wegovy persistence and updated full-year outlook.
- Q4 2026: CagriSema FDA decision expected.
- 1 Jan 2027: lower Wegovy US list price takes effect.
- Falsification: a second guidance cut, Wegovy pill demand fading after launch, CagriSema regulatory failure, or 2027 EPS below DKK 18.5.
Valuation scenarios
| Scenario | 2027E EPS | Exit P/E | 2027 value | Present value | vs price | Weight |
|---|---|---|---|---|---|---|
| Bear | DKK 18.5 ($2.79) | 10x | $27.9 | $25.8 | -30.9% | 25% |
| Base | DKK 22.0 ($3.31) | 13x | $43.1 | $39.9 | +6.8% | 50% |
| Bull | DKK 24.0 ($3.61) | 16x | $57.8 | $53.5 | +43.4% | 25% |
| Probability-weighted value (Estimate) | $39.8 | +6.6% | 100% | |||
Attractive entry zone: $31-$34, subject to stable 2027 earnings expectations. The 3.43% indicated dividend yield is separate from scenario values.
How the market has separated the leaders
Weekly closes indexed to 100 at 31 Dec 2025. Price return only. Novo's 21 September Capital Markets Day coincided with a 7.9% one-day decline as long-term targets failed to reset near-term growth expectations.
Key risks
Pricing and policy
Medicare, Medicaid, PBMs, cash-pay channels and international reimbursement can change net price faster than scripts change. List prices are poor proxies for revenue.
Clinical and safety
Late-stage efficacy does not ensure approval or adherence. EloraTZP Phase 2 discontinuations due to adverse events ranged from 10.8% to 27% across doses.
Concentration
Lilly depends heavily on tirzepatide; Novo depends heavily on semaglutide. Manufacturing or label issues can affect multiple brands at once.
Model and currency
One-year EPS-times-P/E models are highly sensitive to terminal multiples. NVO ADR value also moves with USD/DKK. Paid consensus data were unavailable.
What to watch over the next 1-2 quarters
| Question | Positive evidence | Warning signal |
|---|---|---|
| Can volume outrun price? | Franchise revenue and margin rise together | Scripts rise while revenue or margin stalls |
| Does oral use expand the market? | New starts persist beyond launch stocking | High churn or injection cannibalization |
| Is Lilly's base EPS achievable? | 2027 visibility near $47.5 or higher | Visibility below $41 |
| Can Novo stabilize? | 2027 EPS near DKK 22 and CagriSema approval | Another guide cut or EPS below DKK 18.5 |
| Does supply stay unconstrained? | International launches without shortages | Backorders, facility findings or quality holds |
Methodology and assumptions
- Fact Prices are 2 Oct closes. Market caps, forward P/E, yields and earnings dates are public snapshots accessed 3 Oct 2026.
- Estimate 2027 normalized EPS is $41/$47.5/$54 for LLY and DKK 18.5/22/24 for NVO. Public consensus checks are $47.59 and DKK 22.04 respectively.
- Assumption Exit P/E is 23x/28x/33x for LLY and 10x/13x/16x for NVO. Values are discounted one year at 8%:
2027 EPS x exit P/E / 1.08. - Assumption Scenario probabilities are 25% bear, 50% base and 25% bull. Probability weighting describes the model, not expected return.
- NVO EPS is converted at 6.6421 DKK per USD, the 2 Oct 2026 Yahoo Finance observation. Dividends are excluded from values.
Sources
- Nasdaq LLY quote and NVO quote, 2 Oct close; accessed 3 Oct 2026 03:03 UTC.
- Yahoo Finance LLY chart, Yahoo Finance NVO and DKK=X chart endpoints; accessed 3 Oct 2026 03:03-03:08 UTC.
- StockAnalysis LLY statistics and NVO statistics; market cap, P/E, yield, balance sheet and earnings dates; accessed 3 Oct 2026 03:03 UTC.
- LLY forecast and NVO forecast; S&P Global public consensus snapshots; accessed 3 Oct 2026 03:05 UTC.
- Lilly Q2 2026 results, 5 Aug 2026; accessed 3 Oct 2026.
- Lilly Q2 2026 Form 10-Q, filed 5 Aug 2026; cash, debt and cash flow.
- Lilly TRIUMPH-2 release, 29 Sep 2026; and BioSpace EloraTZP report, 30 Sep 2026.
- Novo Q2 2026 financial report, 4 Aug 2026; accessed 3 Oct 2026.
- Novo 2026 outlook update, 4 Aug 2026.
- Novo Capital Markets Day and CagriSema results, 21 Sep 2026.
- Lilly US government access agreement, and AMCP pricing summary; accessed 3 Oct 2026.
Limitations: no Bloomberg, FactSet or Visible Alpha access; public consensus definitions can differ. Q3 2026 has not yet been reported. All clinical candidates remain subject to regulatory, safety and commercialization risk.